ArticleJournal of radiation research2026
Dosimetric feasibility of carbon-ion radiotherapy for ocular melanomas with local effect model-based treatment planning system.
Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study evaluates the dosimetric feasibility of carbon-ion radiation therapy (CIRT) for ocular melanoma (OM) using a local effect model-I-based treatment planning system (TPS) combined with pencil beam scanning delivery. Cube-shaped targets were designed based on the experience of CIRT for OM at the National Institutes for Quantum Science and Technology (QST). Treatment plans used the local effect model-I-based TPS (Syngo® V13C, SIEMENS, Germany) prescribing an absorbed dose consistent with values reported in the literature. A conversion factor (CF) was established to convert the QST dose to LEM based relative biological effectiveness (RBE)-weighted dose. The physical doses were verified by an in-house Monte Carlo program and measurement. The CF for the LEM, equivalent to the QST RBE-prescribed dose of 70 Gy (RBE) over 5 fractions, was established as 0.65. The 3D gamma passing rate between TPS and MC was ≥94% using 3%-3 mm criteria. Mean dose deviations between the TPS and measurement were ≤±1.61% for all targets sizes except the smallest one (7 mm). Mean distance-to-agreement was <1 mm for all plans except one with a range shifter (distance-to-agreement = 2.92 mm). Phantom cases showed a lateral penumbra of 5.4-6.2 mm, and distal dose fall-off measures 3.6 and 5.6 mm. The results underscore the need for RBE-weighted dose conversion when applying QST's CIRT experience to OM treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.